2023-10-10T08:26:57-05:00 2023-06-30 593040705 RIVERO GORDIMER & COMPANY PA P O BOX 172359 TAMPA FL 33672 990 2022-07-01 593097333 NATIONAL PEDIATRIC CANCER FOUNDATION INC NATI 8132690955 5550 WEST EXECUTIVE DRIVE SUITE 20 TAMPA FL 33609 DAVID FRAZER CHIEF EXECUTIVE OFFICER 8132690955 2023-09-27 1 DAVID FRAZER 999009999 0 SAM A LAZZARA P01342929 8138757774 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z DAVID FRAZER 5550 WEST EXECUTIVE DRIVE SUITE 200 TAMPA FL 33609 6283206 0 X WWW.NATIONALPCF.ORG X 1991 FL THE NPCF IS DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER. 26 25 22 250 0 0 4139918 4618153 0 0 99773 128799 109437 102571 4349128 4849523 2765732 2905436 0 0 988158 1349742 0 0 222633 519864 695897 4273754 4951075 75374 -101552 5857840 6837500 254166 1023962 5603674 5813538 X NATIONAL PEDIATRIC CANCER FOUNDATION (NPCF) IS A NONPROFIT ORGANIZATION DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER. OUR FOCUS IS TO FUND RESEARCH TO FIND LESS TOXIC, MORE TARGETED THERAPIES BY PARTNERING WITH LEADING HOSPITALS NATIONWIDE. 0 0 4360477 2905436 THE NATIONAL PEDIATRIC CANCER FOUNDATION FUNDS PEDIATRIC CANCERRESEARCH WITH THE GOAL OF LEADING TO THE TREATMENT AND ELIMINATION OFPEDIATRIC CANCER WORLDWIDE.WE ACCOMPLISH OUR MISSION THROUGH OUR RESEARCH INITIATIVE, THE SUNSHINEPROJECT, AN INNOVATIVE COLLABORATION OF 30 HOSPITALS NATIONWIDE. THISCOLLABORATIVE RESEARCH MODEL IS UNIQUE AND EFFECTIVE IN ACCELERATINGTHE DEVELOPMENT OF NEW TREATMENTS AGAINST CHILDHOOD CANCER.SEE SCHEDULE O FOR FURTHER PROGRAM SERVICE ACCOMPLISHMENTS.IN DEVELOPING THIS COLLABORATION, THE FOUNDATION HAS BROUGHT TOGETHERSOME OF THE COUNTRY'S LEADING INVESTIGATORS AND INSTITUTIONS TO DRIVETHE PROCESS OF FINDING A CURE. INVESTIGATORS ARE PERFORMING THREE VITALPHASES OF RESEARCH SIMULTANEOUSLY: BASIC SCIENCE, TRANSLATIONALRESEARCH AND CLINICAL TRIALS. THESE MAJOR RESEARCH COMPONENTS NOT ONLYALLOW DOCTORS TO IDENTIFY NEW AGENTS IN FIGHTING CANCER, BUT ALSO HELPRESEARCHERS TO UNDERSTAND THE CANCER CELLS RESPONSE TO THE DRUG.THE NATIONAL PEDIATRIC CANCER FOUNDATION IS MAKING GREAT STRIDES IN ITSMISSION TO FIND A CURE FOR CHILDHOOD CANCER.CURRENT INITIATIVES OF THE SUNSHINE PROJECT ARE AS FOLLOWS:SARCOMA TRIALS (OSTEOSARCOMA, RHABDOMYOSARCOMA, EWING SARCOMA,NON-RHABDOMYOSARCOMA)1. PHASE II STUDY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE FORTREATMENT OF RECURRENT/REFRACTORY SARCOMA IN TEENAGERS AND YOUNG ADULTSTHIS TRIAL WILL LOOK AT THIS COMBINATION OF NAB-PACLITAXEL ANDGEMCITABINE IN ITS ABILITY TO PREVENT THE FORMATION OR GROWTH OF TUMORSIN TEENAGERS AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA,EWING SARCOMA, RHABDOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMA. THETRIAL WILL ALSO LOOK AT THE LENGTH OF TIME DURING AND AFTER TREATMENTTHAT THE DISEASE DOES NOT GET WORSE, AND DETERMINE IF NAB-PACLITAXELCOMBINED WITH GEMCITABINE IS SAFE AND TOLERABLE.2. A PHASE IB/II STUDY TO EVALUATE THE SAFETY, FEASIBILITY AND EFFICACYOF NIVOLUMAB OR NIVOLUMAB IN COMBINATION WITH AZACITIDINE IN PATIENTSWITH RECURRENT, RESECTABLE OSTEOSARCOMA - THIS WILL BE THE FIRST TIMEBOTH DRUGS, NIVOLUMAB AND AZACITIDINE ARE BEING USED IN COMBINATION TOTREAT OSTEOSARCOMA3. EVOLUTIONARY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC,FUSION POSITIVE RHABDOMYOSARCOMA METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA (RMS) HAVE A POOR OUTCOME WHICH IS WORSENED WITH ADDITIONAL RISK FACTORS COMMONLY CALLED THEOBERLIN CRITERIA. PATIENTS THAT MEET ALL 4 OBERLIN CRITERIA HAVE ANEVENT FREE SURVIVAL (EFS) OF LESS THAN 20% AT 2 YEARS. ALL THERAPEUTICARMS ON THIS STUDY ARE DESIGNED TO MEET THE SAME PRIMARY AIM OFIMPROVING THE 3 YEAR EVENT FREE SURVIVAL FROM 6% TO 35% FOR THESEPATIENTS.4. PHASE 1 TRIAL OF THE LSD1 INHIBITOR SP-2577 IN PATIENTS WITHRELAPSED OR REFRACTORY EWING SARCOMA)THIS TRIAL IS A TARGETED TREATMENT FOR INDIVIDUALS DIAGNOSED WITHREFRACTORY OR RECURRENT EWING SARCOMA, AN AGGRESSIVE, SMALL ROUND BLUECELL TUMOR TYPICALLY PRESENTING AS A PRIMARY BONE TUMOR IN CHILDREN ANDYOUNG ADULTS.5. TINKS: A MULTI-INSTITUTION STUDY OF TGF IMPRINTED, EX VIVO EXPANDEDUNIVERSAL DONOR NK CELL INFUSIONS AS ADOPTIVE IMMUNOTHERAPY INCOMBINATION WITH GEMCITABINE AND DOCETAXEL IN PATIENTS WITH RELAPSED ORREFRACTORY PEDIATRIC BONE AND SOFT TISSUE SARCOMAS (IN DEVELOPMENT) -TO DETERMINE THE SAFETY OF THE ADDITION OF ADOPTIVE TRANSFER OFUNIVERSAL DONOR, TGF IMPRINTED (TGFI), EXPANDED NK CELLS TOGEMCITABINE/DOCETAXEL (GEM/DOX) FOR TREATMENT OF RELAPSED ANDREFRACTORY SARCOMAS.BRAIN TUMOR TRIAL1. ACTION : ADOPTIVE CELLULAR THERAPY FOLLOWING DOSE-INTENSIFIEDTEMOZOLOMIDE IN NEWLY-DIAGNOSED PEDIATRIC HIGH-GRADE GLIOMAS - ANIMMUNOTHERAPY TRIAL FOR THE TREATMENT OF HIGH GRADE GLIOMAS (HGG) INCHILDREN.2. EVALUATION OF DIGOXIN FOR RELAPSED NON-WNT, NON-SHH MEDULLOBLASTOMA(IN DEVELOPMENT) THIS TRIAL WILL EVALUATE THE EFFICACY OF DIGOXIN INTREATING PATIENTS WITH RELAPSED NON-SHH, NON-WNT MEDULLOBLASTOMA.NON TREATMENT TRIALS.1. ROLE OF MYELOID-DERIVED SUPPRESSOR CELLS (MDSC) IN THE DEVELOPMENTOF IMMUNE TOLERANCE AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION(ALLOHCT) -THIS IS AN OBSERVATIONAL TRIAL WITH GOAL OF BETTERUNDERSTANDING THE PROCESS OF DEVELOPING IMMUNE TOLERANCE AFTER BLOODAND MARROW TRANSPLANTATION (BMT).2. BLOOD BASED BIOMARKERS FOR MINIMAL RESIDUAL DISEASE DETECTION INPEDIATRIC SARCOMAS - THE PURPOSE OF THIS STUDY IS TO SEE IF DETECTINGCELL-FREE PLASMA TUMOR DNA (PTDNA) AND CIRCULATING TUMOR CELLS (CTC)CAN PREDICT RECURRENCE OF DISEASE IN PATIENTS WHO ARE IN RADIOGRAPHICREMISSION 2-3 WEEKS AFTER TREATMENT. PLASMA TUMOR DNA (PTDNA) IS FREEFLOATING DNA FROM THE TUMOR FOUND IN THE BLOOD STREAM AND CIRCULATINGTUMOR CELLS.3. PEDIATRIC TOTAL CANCER CARE- THIS TRIAL FOCUSES ON TISSUE AND BLOODCOLLECTION TO FURTHER PERSONALIZED MEDICINE FOR CHILDREN WITH CANCERTISSUE SAMPLE STUDIES.1. COMPREHENSIVE MOLECULAR PROFILING OF RARE PEDIATRIC AND AYA CANCERS- DEVELOPMENT OF AN INFRASTRUCTURE, METHODS, AND STANDARD OPERATINGPROCEDURE TO COLLECT AND PROCURE HISTOLOGY SPECIFIC(ESTHESIONEUROBLASTOM AND EMBRYONAL SARCOMA) TISSUE RESOURCES AVAILABLETHROUGHOUT THE SUNSHINE PROJECT AND ASSOCIATED REPOSITORIES.CHART REVIEW STUDY.1. COMPREHENSIVE GENETIC PROFILING FOR PEDIATRIC MALIGNANCIESONGOING PRE-CLINICAL TRIALS.1. ASSESSMENT OF EXPANDED TUMOR INFILTRATING NK-CELLS COLLABORATIVE.2. DEVELOPMENT OF PERSONALIZED RNA LOADED NANOPARTICLES.3. FUSION PROTEINS BY IMMUNOTHERAPY.SUNSHINE PROJECT LABORATORYTHE SUNSHINE LAB CONTINUES WITH THE IMPORTANT TASK OF FINDING PROMISINGNEW TREATMENT REGIMENS FOR SARCOMAS, AMONG THE MOST DEADLY PEDIATRICCANCER.DURING THIS PAST YEAR, THE SUNSHINE LAB HAS BUILT ON COMBINATION DRUGSCREENING PLATFORM AND FOCUSED ON OSTEOSARCOMA AND EWING SARCOMA.PEDIATRIC SARCOMAS OFTEN SHRINK OR GO AWAY WITH INITIAL THERAPY BUTTHEN LATER RELAPSE AND ARE THEN MUCH MORE DIFFICULT TO CURE. THISSUGGESTS THAT A SMALL AMOUNT OF DISEASE ELUDES CURRENT THERAPY.WE CONSIDER THIS SMALL, RESISTANT POPULATION SHOULD BE THE FOCUS OFPRECLINICAL RESEARCH AND HAVE 3 MAJOR PROJECTS RESULTING FROM THATUNDERSTANDING OF PEDIATRIC SARCOMA. 1. WE HAVE DEVELOPED A MODEL OF THESE TWO COMPETING POPULATIONS,TERMED HETEROGENEITY, TO FIGURE OUT THE BEST STRATEGY TO ELIMINATE BOTHCANCER CELL POPULATIONS WITH TIMING AND COMBINATIONS OF THERAPIES. 2. IN COLLABORATION, WE ARE INVESTIGATING "SECOND STRIKES" IN BOTHOSTEOSARCOMA AND EWING SARCOMA. SECOND STRIKES ARE THERAPIES AFTER THEDISEASE HAS SHRUNK WITH INITIAL THERAPY. RATHER THAN SHRINK THE TUMOR,WE ARE INVESTIGATING THERAPIES TO ELIMINATE THE RESIDUAL CELLS BETTERTHAN CONTINUING THE INITIAL THERAPY (FIRST STRIKE). THIS RESULTED FROMTHE SUNSHINE LAB PARTICIPATING IN THE 9TH ANNUAL INTEGRATEDMATHEMATICAL ONCOLOGY WORKSHOP AT MOFFITT CANCER CENTER. 3. IN COLLABORATION, WE HAVE FOCUSED ON A NEW, NON-MUTATED TARGET INOSTEOSARCOMA, THE CMG HELICASE. WE HAVE BOTH IDENTIFIED THIS AS AWEAKNESS IN CANCER CELLS MORE THAN NORMAL CELLS AND IDENTIFIED A DRUGCLASS THAT HOLDS PROMISE AS AN EVENTUAL THERAPY. WE ARE EXPLORING THISAGENT ALONE AND IN COMBINATION TO MAXIMIZE THE CHANCE FOR A SUCCESSFULCLINICAL TRIAL. 4. IN COLLABORATION, WE ARE BUILDING ON PRIOR PUBLICATIONS SHOWACTIVITY OF EPIGENETIC DRUGS LIKE PANOBINOSTAT AND EXPLORING MECHANISMSTO ENHANCE THIS THERAPY IN OSTEOSARCOMA. 5. IN COLLABORATION, WE ARE INVESTIGATING AN UNDERAPPRECIATED DNAREPAIR ENZYME AS AN ACHILLES HEEL IN EWING SARCOMA CALLED PARP16. 4360477 1 1 0 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 1 88 0 1 22 0 0 0 0 0 0 1 1 0 0 0 0 X 26 25 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 FL AL AK CA CO CT DC GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VT VA WA WV WI X X X NATIONAL PEDIATRIC CANCER FOUNDATION INC 8132690955 5550 WEST EXECUTIVE DRIVE SUITE 200 TAMPA FL 33609 DAVID FRAZER CEO 40.00 X 202218 0 0 MICHAEL LEVIN CHAIRMAN OF THE BOARD 2.00 X X 0 0 0 CHAD HARROD VICE CHAIRMAN 2.00 X X 0 0 0 AL SILVA VICE CHAIRMAN 2.00 X X 0 0 0 JEREMY PERSINGER TREASURER 2.00 X X 0 0 0 JIM BASSIL SECRETARY 2.00 X X 0 0 0 ALEX SULLIVAN PAST CHAIRMAN 1.00 X 0 0 0 MELISSA DUNKEL CO-FOUNDER AT LARGE (EMERI 1.00 X 0 0 0 CHRIS CARRERE AT LARGE 1.00 X 0 0 0 FRANK CAPITANO AT LARGE 1.00 X 0 0 0 JEFF MAXWELL AT LARGE 1.00 X 0 0 0 RICHARD HUFF AT LARGE 1.00 X 0 0 0 BB ABBOTT DIRECTOR 1.00 X 0 0 0 CARRIE CHARLES DIRECTOR 1.00 X 0 0 0 DAN DOYLE JR DIRECTOR 1.00 X 0 0 0 JOHN FITZPATRICK DIRECTOR 1.00 X 0 0 0 DAVID BOYINGTON DIRECTOR 1.00 X 0 0 0 JOSEPH LAMPHIER DIRECTOR 1.00 X 0 0 0 JAY LANGFORD DIRECTOR 1.00 X 0 0 0 PHILIP MINARDI DIRECTOR 1.00 X 0 0 0 ANGELA NORTH DIRECTOR 1.00 X 0 0 0 MARK MCHUGH DIRECTOR 1.00 X 0 0 0 DAWN SILER-NIXON DIRECTOR 1.00 X 0 0 0 JOE TAGGART DIRECTOR 1.00 X 0 0 0 MIKE WEIGNER DIRECTOR 1.00 X 0 0 0 THOMAS GROSSJUNG DIRECTOR 1.00 X 0 0 0 MARCO SCHNABL DIRECTOR 1.00 X 0 0 0 202218 0 0 1 0 1 0 0 1103462 3514691 359390 4618153 128799 128799 1536254 1103462 1433683 102571 102571 4849523 0 0 231370 2892211 2892211 13225 13225 202218 149847 41989 10382 1005963 767317 191982 46664 38281 28384 6169 3728 103280 71606 22281 9393 9196 9196 21200 21200 29529 29529 75754 58602 17152 129344 99158 12140 18046 31003 18906 7775 4322 79180 63490 12200 3490 38760 32080 5000 1680 6587 448 6139 12019 456 1067 10496 34144 29502 2996 1646 42423 38520 2278 1625 25658 22275 2071 1312 CONTRACT LABOR 46955 39243 4632 3080 POSTAGE AND SHIPPING 27954 4273 652 23029 PRINTING AND REPRODUCTI 23166 15830 3037 4299 DONOR RELATIONS 735 61 87 587 62290 5847 880 55563 4951075 4360477 367965 222633 571038 809161 60273 123012 1607445 84662 1896 1522783 4454003 4076098 531379 299524 246173 5857840 6837500 254166 107769 38800 877393 254166 1023962 X 5320323 5503653 283351 309885 5603674 5813538 5857840 6837500 -101552 341392 -29976 0 X X 0 1 X 1 0 X 3484557 3247093 4078949 3578042 3041195 17429836 3484557 3247093 4078949 3578042 3041195 17429836 1069035 16360801 91265 61466 958567 99773 128799 1339870 18769706 2895120 0.87170 0.88290 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1904761 30479 162758 2097998 2194890 25172 -315301 1904761 1013600 883542 297748 2194890 923363 100000 -9763 1013600 801728 100000 21635 923363 0.88000 0.04000 0.08000 0 0 1545000 38965 1506035 62445 45697 16748 1522783 X 5175753 341392 14814 356206 4819547 29976 29976 4849523 4965889 14814 14814 4951075 0 4951075 PART X, LINE 2: THE FOUNDATION HAS RECEIVED A DETERMINATION OF TAX EXEMPT STATUS UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. ACCORDINGLY, NO PROVISION FOR INCOME TAXES IS REFLECTED IN THE ACCOMPANYING FINANCIAL STATEMENTS. MANAGEMENT IS NOT AWARE OF ANY ACTIVITIES THAT WOULD JEOPARDIZE THE FOUNDATION'S TAX EXEMPT STATUS. THE FOUNDATION IS NOT AWARE OF ANY TAX POSITIONS IT HAS TAKEN THAT ARE SUBJECT TO A SIGNIFICANT DEGREE OF UNCERTAINTY. TAX YEARS AFTER JUNE 30, 2019 REMAIN SUBJECT TO EXAMINATION BY TAXING AUTHORITIES. PART V, LINE 4: THE NATIONAL PEDIATRIC CANCER FOUNDATION MAINTAINS AN ENDOWMENT FUND AT THE COMMUNITY FOUNDATION OF TAMPA BAY, INC. FOR THE LONG TERM BENEFIT OF THE NATIONAL PEDIATRIC CANCER FOUNDATION. FASHION FUNDS THE CURE 1709705 669268 1040437 828569 FISHING FUNDS THE CURE 476382 100388 375994 341302 6 453628 333805 119823 263812 2639715 1103461 1536254 1433683 1433683 102571 1 H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238636 501(C)(3) 100000 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 487062 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(C)(3) 770000 0 TWO RESEARCH STUDY GRANTS " TARGETING THE TUMOR MICROENVIRONMENT OF METASTASIS TO TREAT METASTATIC EWING SARCOMA AND"RE-PURPOSING HIV NUCLEOSIDE REVERSE TRANSCRIPTAS INHIBITORS FOR HIGH RISK NEROBLASTOME THERAPY" CHILDREN'S HOSPITAL OF COLORADO FOUNDATION 13123 E 16TH AVE AURORA CO 80045 840813462 501(C)(3) 109377 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. UNIVERSITY OF FLORIDA PO BOX 115500 GAINESVILLE FL 32611 596002052 501(C)(3) 78516 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. UNIVERSITY OF COLORADO MS F428 AMC BLDG 500 AURORA CO 80045 846000555 501(C)(3) 64688 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. CONNECTICUT CHILDREN'S MEDICAL CENTER 282 WASHINGTON ST HARTFORD CT 06106 222619869 501(C)(3) 56768 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. DUKE UNIVERSITY PO BOX 104132 DURHAM NC 27708 560532129 501(C)(3) 24093 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVE SUITE 700 NASHVILLE TN 37203 352528741 501(C)(3) 19750 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVE CLEVELAND OH 44195 340714585 501(C)(3) 16922 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. CHILDREN'S NATIONAL MEDICAL CENTER 111 MICHIGAN AVE NW WASHINGTON DC 20010 521640403 501(C)(3) 24688 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. NATIONWIDE CHILDREN'S HOSPITAL 700 CHILDRENS DR COLUMBUS OH 43205 311036372 501(C)(3) 32923 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. PARATOPE BIO INC 1013 CENTRE RD SUITE 403-A WILMINGTON DE 19805 920860458 700000 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 10889 WILSHIRE BLVD SUITE 700 LOS ANGELES CA 90095 943067788 501(C)(3) 400000 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. ST JOSEPH'S HOSPITAL INC 295 DREW ST CLEARWATER FL 33579 590774199 501(C)(3) 6402 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. SAFETY NET GRANT FOR REIMBURSABLE MEDICAL EXPENSES NOT COVERED BY INSURANCE 10 13225 FMV X X 0 0 0 0 0 0 0 0 0 DAVID FRAZER CEO 183636 0 18582 0 0 0 0 0 0 0 202218 0 0 0 CHAD HARROD VICE CHAIRMAN OF THE BOARD OF DIRECTORS OF NPCF. 1551306 SEE BELOWTHE FOUNDATION OCCUPIED OFFICE SPACE IN A PROPERTY OWNED BY A HARROD PROPERTIES COMPANY (RELATED PARTY), WHICH RESULTED IN CONTRIBUTED RENT OF $6,306 DURING THE YEAR ENDED JUNE 30, 2023. IN JULY 2022, THE FOUNDATION ENTERED INTO AN AGREEMENT TO PURCHASE ITS OFFICE SPACE FROM THE RELATED PARTY FOR $1,545,000, WHICH INCLUDED A NON-CASH CONTRIBUTION OF $345,000 FROM THE RELATED PARTY. CHAD HARROD IS THE PRESIDENT OF HARROD PROPERTIES, INC. 0 X 1 345000 FAIR MARKET VALUE X SPECIAL EVENTS 13 32964 FAIR MARKET VALUE X RENT 1 6306 FAIR MARKET VALUE 0 1 1 PART I, LINE 32B: AN UNRELATED THRID PARTY IS USED TO RECEIVE, PROCESS AND SELL ALL VEHICLE DONATIONS. FORM 990, PART VI, SECTION B, LINE 11B THE BOARD OF DIRECTORS RECEIVES THE DRAFT OF THE FORM 990 AND APPROVES THE FORM 990 PRIOR TO THE FORM BEING FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION'S CONFLICT OF INTEREST POLICY IS DISCUSSED AT ORIENTATION OF OFFICERS AND DIRECTORS ON A PERIODIC BASIS, AT LEAST ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION FOR THE CEO AND OTHER KEY EMPLOYEES IS REVIEWED AND APPROVED BY THE EXECUTIVE COMMITTEE AND BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 THE NATIONAL PEDIATRIC CANCER FOUNDATION MAKES ITS GOVERNING DOCUMENTS, PRIVACY POLICY AND FINANCIAL INFORMATION AVAILABLE FOR PUBLIC INSPECTION THROUGH THE ORGANIZATION'S WEBSITE AS WELL AS UPON REQUEST. FORM 990, PART XII, LINE 2C, FINANCIAL STATEMENTS AND REPORTING THE PROCESS FOR OVERSIGHT OF THE AUDIT AND SELECTION OF AN INDEPENDENT ACCOUNTANT HAS NOT CHANGED FROM THE PRIOR YEAR.